Our impact
Discover our impact, and the differences we're aiming to make for people affected by cancer.
Cancer Research Campaign Technology appoints CRV as exclusive agent
On 16th January 2001 Cancer Research Ventures (CRV) was appointed the exclusive agent of Cancer Research Campaign Technology (CRCT) for the purposes of conducting all new technology transfer business derived from research funded by The Cancer Research Campaign (The CRC).
The addition of the rich source of cancer technologies emanating from The CRC, expands CRV’s technology transfer and development business to include the majority of UK cancer funders as well as including many clients in Europe. CRV will also be strengthened by the addition of the staff and assets of CRCT to the CRV operations.
- 24 January 2001
Related content
Drug discovery and development
We identify, develop and commercialise promising ideas into successful cancer therapeutics, diagnostics and enabling technologies.
Hummingbird Bioscience announces UK MHRA approval for first-in-human phase 1 trial of HMBD-001 in advanced cancers
Hummingbird Bioscience announced that the UK Medicines and Healthcare Products Regulatory Agency has approved the clinical trial application to initiate first-in-human phase 1 trial of HMBD-001 in patients with advanced cancers.